VEGFA rs699946: What Your Genotype Means
The single nucleotide polymorphism rs699946 is a common functional variation located in the promoter region of the VEGFA gene, historically referenced in medical research as -2578C>A. By modulating how vascular endothelial growth factor A is expressed, this variant has been examined for its associations with blood vessel formation and vascular complications such as preeclampsia and recurrent pregnancy loss. However, evidence remains limited and varies across different global ancestral populations.
What each genotype means
Typical angiogenic expression
You carry two copies of the common C allele in the VEGFA promoter region. This genotype is associated with baseline vascular endothelial growth factor expression and typical vascular remodeling. Published studies link this profile to standard population risk for pregnancy-related vascular conditions such as preeclampsia, though overall evidence remains limited.
Carried by roughly 40% to 50% of individuals of European ancestry and more than 70% of individuals of African ancestry.
Intermediate angiogenic profile
You have one copy of the A minor allele and one copy of the C allele. Research indicates intermediate VEGFA promoter activity and slight modulation of circulating VEGF levels. In epidemiological research, this genotype has been evaluated for modest differences in preeclampsia and microvascular risk, but evidence remains mixed and inconclusive.
Carried by approximately 40% to 45% of individuals of European descent and about 25% of individuals of African descent.
Altered angiogenic expression
You carry two copies of the A minor allele in the promoter region of the VEGFA gene. Some candidate-gene studies have linked this genotype to lower VEGFA expression and a modest statistical increase in susceptibility to preeclampsia and diabetic microvascular traits. However, findings across diverse populations are inconsistent and the overall clinical evidence strength is considered limited.
Carried by roughly 10% to 12% of individuals of European ancestry and approximately 2% to 3% of individuals of African ancestry.
Genomic Location and Variant Characteristics
The single nucleotide polymorphism rs699946 is situated on chromosome 6 in the 5-prime upstream promoter region of the human VEGFA (vascular endothelial growth factor A) gene. In dbSNP, it is documented as a single-base variation involving cytosine (C) and adenine (A) alleles. In older scientific literature, this polymorphism is frequently designated as VEGF -2578C>A or -2578A/C based on its distance relative to the transcription initiation site. Because it resides within a non-coding regulatory promoter zone, rs699946 does not change the amino acid sequence of the final protein. Instead, laboratory and expression quantitative trait loci (eQTL) investigations suggest that this base change can alter local transcription factor binding affinities and chromatin accessibility. As a result, differing genotypes at rs699946 can influence basal or hypoxia-induced transcriptional activity of the VEGFA gene, shifting systemic and localized vascular growth factor concentrations.
The Biological Role of VEGFA in Vascular Remodeling
The VEGFA gene produces vascular endothelial growth factor A, a vital signaling protein that stimulates physiological angiogenesis, endothelial cell survival, proliferation, and vascular permeability. Normal blood vessel development depends heavily on tightly regulated VEGFA levels. During human pregnancy, VEGFA plays an essential role in maternal-fetal circulation by coordinating the remodeling of maternal spiral arteries and promoting proper placental vascularization. Beyond reproduction, VEGFA signaling is critical throughout adult life for wound healing, collateral vessel formation during cardiovascular ischemia, and microvascular maintenance in organs such as the retina and kidneys. Because angiogenic pathways require a delicate homeostatic balance, minor alterations in promoter-driven VEGFA expression can have wide-ranging physiological effects, influencing individual susceptibility to endothelial dysfunction, microvascular damage, and ischemic complications.
Clinical Research: Preeclampsia and Microvascular Traits
A substantial body of research has investigated rs699946 in connection with vascular conditions of pregnancy, notably preeclampsia and recurrent pregnancy loss. Some observational studies and meta-analyses suggest that carriers of specific promoter alleles experience altered placental angiogenesis, contributing to defective trophoblast invasion and elevated maternal endothelial stress. However, published findings remain mixed: while certain cohorts demonstrate a statistically significant correlation between the A allele (or specific haplotypes) and increased risk for preeclampsia, other regional studies fail to replicate the finding, highlighting potential ethnic and environmental stratification. Outside of obstetrics, rs699946 has been evaluated in microvascular diseases such as diabetic retinopathy and nephropathy, as well as cardiovascular traits. Despite these biological links, statistical associations in candidate gene studies have exhibited variable effect sizes, leading genetics databases to classify the overall clinical predictive evidence as limited.
Population Distribution and Genetic Linkage
Allele frequencies for rs699946 vary considerably across diverse global ancestries. In European populations, the minor allele frequency is approximately 0.33, while in African populations, it is generally lower at around 0.15. Across East Asian and South Asian groups, the variant exhibits distinct intermediate distribution patterns. Notably, rs699946 does not act entirely in isolation; it frequently exists in strong linkage disequilibrium with adjacent regulatory variants in the VEGFA promoter, such as rs1570360 (-1154G>A) and rs833061 (-1498C>T), as well as downstream variations like rs2010963 (+634G>C). Because these variations are frequently inherited together as multi-variant promoter haplotypes, researchers often find that evaluating combined haplotype blocks provides a clearer picture of promoter activity than examining rs699946 alone.
Understanding Limitations: What This Variant Cannot Tell You
Understanding your rs699946 genotype provides educational insight into baseline angiogenic gene regulation, but it carries strict limitations. This polymorphism is not a diagnostic test. Carrying a genotype linked with lower or higher VEGF expression does not mean an individual will develop preeclampsia, recurrent pregnancy loss, or microvascular complications. Complex vascular conditions are multifactorial, driven by dozens of polygenic factors, maternal age, preexisting cardiovascular health, diet, metabolic markers, and lifestyle habits. Commercial genetic profiling for rs699946 cannot replace routine clinical care, prenatal monitoring, blood pressure checks, or standard obstetric screenings. Individuals with questions regarding pregnancy complications or vascular health should review their clinical history with a qualified healthcare provider or certified genetic counselor rather than altering medical decisions based on single-variant results.
How common is this variant?
The minor allele frequency of rs699946 is approximately 0.33 in populations of European ancestry, compared to approximately 0.15 in African populations, with varying intermediate frequencies observed across Asian populations.
Frequently asked questions
What is the difference between rs699946 and VEGF -2578C>A?
They refer to the exact same genetic variant. The label rs699946 is the official database accession number cataloged in dbSNP, whereas -2578C>A is a classical notation describing its position 2,578 base pairs upstream from the VEGFA gene's transcription start site.
Can testing rs699946 predict whether I will get preeclampsia?
No, it cannot diagnose or reliably predict preeclampsia. Preeclampsia is a complex, multifactorial disorder influenced by multiple maternal genes, placental physiology, cardiovascular health, and environmental factors, making single-SNP testing clinically insufficient.
Does my rs699946 genotype affect medication response?
Currently, rs699946 does not have CPIC or PharmGKB clinical prescribing guidelines for medication dosing. While anti-VEGF therapies exist for oncology and retinal disorders, treatment decisions are guided by clinical pathology rather than this specific promoter variant.
Why do different studies show conflicting results for this variant?
Candidate gene association studies often differ due to small sample sizes, distinct ancestral backgrounds, and variable environmental factors. Furthermore, rs699946 acts within larger promoter haplotypes, meaning its biological impact can vary depending on adjacent variations.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs699946?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29